- Home
- Publications
- Publication Search
- Publication Details
Title
GPCR Inhibition in Treating Lymphoma
Authors
Keywords
-
Journal
ACS Medicinal Chemistry Letters
Volume -, Issue -, Pages -
Publisher
American Chemical Society (ACS)
Online
2022-02-15
DOI
10.1021/acsmedchemlett.1c00600
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Macrocycle Therapeutics to Treat Life-threatening Diseases
- (2021) Gokhan Batur et al. CHIMIA
- Methods for the synthesis of immunostimulant plerixafor
- (2020) Nina K. Ratmanova et al. Chemistry of Heterocyclic Compounds
- Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
- (2020) A. Arribas et al. EUROPEAN JOURNAL OF CANCER
- CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas
- (2019) Linfeng Chen et al. HAEMATOLOGICA
- The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro
- (2019) Katrin Pansy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Modulators of CXCR4 and CXCR7/ACKR3 function
- (2019) Ilze Adlere et al. MOLECULAR PHARMACOLOGY
- Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
- (2018) Clara Recasens-Zorzo et al. HAEMATOLOGICA
- Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
- (2018) Clara Recasens-Zorzo et al. HAEMATOLOGICA
- 322PAnti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide
- (2018) J Zimmermann et al. ANNALS OF ONCOLOGY
- Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations
- (2017) Yoonji Lee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
- (2015) Jiayu Chen et al. Oncotarget
- Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
- (2014) S.-B. Peng et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
- (2013) K. Beider et al. CLINICAL CANCER RESEARCH
- The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
- (2013) A. Peled et al. CLINICAL CANCER RESEARCH
- Small Molecule Inhibitors of CXCR4
- (2013) Bikash Debnath et al. Theranostics
- Noncyclam Tetraamines Inhibit CXC Chemokine Receptor Type 4 and Target Glioma-Initiating Cells
- (2012) Laia Ros-Blanco et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
- (2011) K. O'Callaghan et al. BLOOD
- Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists
- (2011) Yanping Hu et al. LEUKEMIA & LYMPHOMA
- Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
- (2010) Renato T. Skerlj et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4
- (2009) Veronique Bodart et al. BIOCHEMICAL PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started